Divakaran, Sanjay
Lopez, Diana M.
Parks, Sean M.
Hainer, Jon
Ng, Andrea K.
Blankstein, Ron
Di Carli, Marcelo F.
Nohria, Anju
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (5P30AG031679-10, T32 HL094301)
Article History
Received: 19 June 2022
Accepted: 9 January 2023
First Online: 20 January 2023
Declarations
:
: The Mass General Brigham Institutional Review Board approved this study and waived the need for informed consent.
: Not applicable.
: Dr. Divakaran receives consulting fees from Kinevant Sciences. Dr. Blankstein receives research support from Amgen Inc. and Astellas Inc. Dr. Di Carli has received investigator-initiated institutional research grant support from Spectrum Dynamics and Gilead Sciences, and consulting fees from Bayer and Janssen. Dr. Nohria receives consulting fees from Takeda Oncology, AstraZeneca Pharmaceuticals, and Bantam Pharmaceuticals and research support from Bristol Myers Squibb. All other authors report that they have no relationships relevant to the contents of this paper to disclose.